Calcium dibutyryladenosine cyclophosphate is a widely used cardiovascular drug.The traditional batch synthesis process suffers from long reaction times,tedious operations,and unstable yields.Herein,a sequential contin...Calcium dibutyryladenosine cyclophosphate is a widely used cardiovascular drug.The traditional batch synthesis process suffers from long reaction times,tedious operations,and unstable yields.Herein,a sequential continuous flow synthesis combined with a multistage in-line purification process of calcium dibutyryladenosine cyclophosphate was developed.The acylation reaction was completed in a continuous coil reactor at 160℃ in 20 min.And the high toxic solvent pyridine was replaced by acetonitrile.Furthermore,the multistage in-line purification process was integrated into the homemade 3D circular cyclone-type micromixer chip.Combining with the membrane phase separators,the residence time of the purification step was 30 s.The isolated yield of this sequential continuous process was 92%with 99%purity.展开更多
目的探讨脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛的临床疗效。方法选取2015年7月—2016年7月在达州市达川区人民医院进行治疗的不稳定型心绞痛患者64例,根据治疗方案的差别分为对照组(32例)和治疗组(32例)。对照组患者静脉滴...目的探讨脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛的临床疗效。方法选取2015年7月—2016年7月在达州市达川区人民医院进行治疗的不稳定型心绞痛患者64例,根据治疗方案的差别分为对照组(32例)和治疗组(32例)。对照组患者静脉滴注注射用二丁酰环磷腺苷钙,40 mg加入5%葡萄糖注射液250 m L,1次/d。治疗组在对照组的基础上口服脉血康胶囊,4粒/次,3次/d。两组患者均治疗4周。评价两组治疗后患者临床疗效,同时比较治疗前后两组患者心绞痛改善情况、氧化应激水平、血管内皮功能和炎性因子水平变化。结果治疗后,对照组和治疗组的总有效率分别为81.25%、93.75%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,两组患者心绞痛发作次数、发作持续时间、心电图ST段压低数和心电图T波总倒置数均较同组治疗前明显降低(P<0.05);且治疗组患者比对照组降低的更显著(P<0.05)。与治疗前相比,治疗后两组血清丙二醛(MDA)水平显著降低,超氧化物歧化酶(SOD)活性显著升高,同组比较差异具有统计学意义(P<0.05);且治疗组上述指标改善的更显著(P<0.05)。治疗后,两组患者血清内皮素-1(ET-1)水平明显降低,NO水平明显增高,同组比较差异具有统计学意义(P<0.05);且治疗后治疗组患者上述血管内皮功能优于对照组(P<0.05)。治疗后,两组血清超敏C反应蛋白(hs-CRP)、白细胞介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)水平均显著降低(P<0.05);且治疗后治疗组患者炎性因子水平比对照组更低(P<0.05)。结论脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛效果显著,可显著改善血管内皮功能和降低氧化应激反应,具有一定的临床推广应用价值。展开更多
基金supported by the National Natural Science Foundation of China(No.22278087)。
文摘Calcium dibutyryladenosine cyclophosphate is a widely used cardiovascular drug.The traditional batch synthesis process suffers from long reaction times,tedious operations,and unstable yields.Herein,a sequential continuous flow synthesis combined with a multistage in-line purification process of calcium dibutyryladenosine cyclophosphate was developed.The acylation reaction was completed in a continuous coil reactor at 160℃ in 20 min.And the high toxic solvent pyridine was replaced by acetonitrile.Furthermore,the multistage in-line purification process was integrated into the homemade 3D circular cyclone-type micromixer chip.Combining with the membrane phase separators,the residence time of the purification step was 30 s.The isolated yield of this sequential continuous process was 92%with 99%purity.
文摘目的探讨脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛的临床疗效。方法选取2015年7月—2016年7月在达州市达川区人民医院进行治疗的不稳定型心绞痛患者64例,根据治疗方案的差别分为对照组(32例)和治疗组(32例)。对照组患者静脉滴注注射用二丁酰环磷腺苷钙,40 mg加入5%葡萄糖注射液250 m L,1次/d。治疗组在对照组的基础上口服脉血康胶囊,4粒/次,3次/d。两组患者均治疗4周。评价两组治疗后患者临床疗效,同时比较治疗前后两组患者心绞痛改善情况、氧化应激水平、血管内皮功能和炎性因子水平变化。结果治疗后,对照组和治疗组的总有效率分别为81.25%、93.75%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,两组患者心绞痛发作次数、发作持续时间、心电图ST段压低数和心电图T波总倒置数均较同组治疗前明显降低(P<0.05);且治疗组患者比对照组降低的更显著(P<0.05)。与治疗前相比,治疗后两组血清丙二醛(MDA)水平显著降低,超氧化物歧化酶(SOD)活性显著升高,同组比较差异具有统计学意义(P<0.05);且治疗组上述指标改善的更显著(P<0.05)。治疗后,两组患者血清内皮素-1(ET-1)水平明显降低,NO水平明显增高,同组比较差异具有统计学意义(P<0.05);且治疗后治疗组患者上述血管内皮功能优于对照组(P<0.05)。治疗后,两组血清超敏C反应蛋白(hs-CRP)、白细胞介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)水平均显著降低(P<0.05);且治疗后治疗组患者炎性因子水平比对照组更低(P<0.05)。结论脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛效果显著,可显著改善血管内皮功能和降低氧化应激反应,具有一定的临床推广应用价值。
